Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treating elevated lipids. Does it make a difference?

J Best1, D O'Neal

  • 1Department of Medicine, St Vincent's Hospital, Victoria.

Australian Family Physician
|April 29, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing the efficacy, safety and utility of fully closed-loop insulin delivery compared to standard insulin therapy with a continuous glucose monitor in adults with type 2 diabetes (COYOTE study): a randomised parallel study protocol.

BMJ open·2026
Same author

Real-time x-ray abnormality alerts for emergency departments using a radiographer comment model - a multisite pilot study.

Radiography (London, England : 1995)·2023
Same author

Coronavirus Disease 2019: the Pivotal Role of UK Clinical Oncology and the UK Coronavirus Cancer Monitoring Project.

Clinical oncology (Royal College of Radiologists (Great Britain))·2020
Same author

Negative effects of the sea lice therapeutant emamectin benzoate at low concentrations on benthic communities around Scottish fish farms.

The Science of the total environment·2019
Same author

Homeostasis despite instability.

Mathematical biosciences·2018
Same author

The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.

Zeitschrift fur Gastroenterologie·2016
Same journal

Occupational violence and staff safety in general practice.

Australian family physician·2018
Same journal

You should get that mole checked out: Ethical and legal considerations of the unsolicited clinical opinion.

Australian family physician·2018
Same journal

Understanding the decision to commence a dose administration aid.

Australian family physician·2018
Same journal

Psychological distress and risky sexual behaviours among women aged 16-25 years in Victoria, Australia.

Australian family physician·2018
Same journal

A mixed-methods feasibility study of routinely weighing patients in general practice to aid weight management.

Australian family physician·2018
Same journal

The Australian Mid-West Coastal Marine Wound Infections Study.

Australian family physician·2018
See all related articles

Lipid-lowering therapy significantly reduces coronary heart disease (CHD) event risk by approximately 30%. High-risk individuals experience the greatest absolute benefit from cholesterol-lowering medications.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Clinical trials demonstrate that lipid-modifying therapy reduces coronary heart disease (CHD) risk.
  • Treatment decisions require balancing costs and benefits.

Purpose of the Study:

  • To evaluate the cardiovascular benefits of cholesterol-lowering medications.
  • Assessed evidence from primary and secondary prevention studies.

Main Methods:

  • Systematic review of clinical trials.
  • Analysis of primary and secondary prevention studies.

Main Results:

  • Cholesterol-lowering treatment reduces relative risk of major CHD events by ~30%.
  • Highest benefit observed in high-risk populations due to greater absolute risk reduction.

Related Experiment Videos

  • Moderate-risk individuals require more treatment to prevent one event compared to high-risk individuals.

    • Conclusions:

    • Treating hypercholesterolemia offers significant cardiovascular benefits.
    • Lipid-lowering therapy is most impactful in high-risk patient groups.
    • The benefit in moderate-risk groups is comparable to primary stroke prevention via hypertension management.